Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	lung adenocarcinoma
ICD-0-3	C34
Methods	qPCR, Western blot etc.
Sample	cell lines (A549, H460, H1299, BES-2B and HEK-293T)
Expression Pattern	up-regulated
Function Description	DGCR5 was upregulated in LUAD tissues and LUAD cell lines.Inhibition of DGCR5 can prevent LUAD progression via playing anti-apoptosis roles.Both mRNA expression and protein levels of BCL-2 were increased by DGCR5 downregulation while reversely BAX was increased. Additionally,a novel microRNA target of DGCR5,hsa-mir-22-3p was identified through bioinformatics search and confirmed by dual-luciferase reporter system. Gain and loss-of-function studies were performed to verify whether DGCR5 exerts its biological functions through regulating hsa-mir-22-3p in vitro. Overexpression of DGCR5 was able to reverse the tumor inhibitory effect of hsa-mir-22-3p mimics. Furthermore, in vivo tests tumor xenografts were established to detect the function of DGCR5 in LUAD tumorigenesis. Downregulated DGCR5 expression was greatly associated with smaller tumor size,implying a favorable prognosis of LUAD patients.Taken these together,DGCR5 could be considered as a prognostic biomarker and therapeutic target in LUAD diagnosis and treatment.
Pubmed ID	29030962
Year	2018
Title	LncRNA DGCR5 promotes lung adenocarcinoma (LUAD) progression via inhibiting hsa-mir-22-3p.

External Links